Discover
INMB
INmune Bio Inc.
1.68
2 x 1.24
2 x 2.11
bid
ask
+
0.05
3.07%
2 @ 05:25 AM
1.67 -0.01 (0.62%)
| Ytd | 7.69% | |
| 1y | -19.62% |
1.62
day range
1.73
1.09
52 week range
3.24
| Open | 1.62 | Prev Close | 1.63 | Low | 1.62 | High | 1.73 | Mkt Cap | 44.66M |
| Vol | 748.52K | Avg Vol | 627.18K | EPS | -1.63 | P/E | N/A | Forward P/E | -2.23 |
| Beta | 1.85 | Short Ratio | 18.08 | Inst. Own | 24.32% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.41 | 200-d Avg | 1.56 | 1yr Est | 19.83 |
INMB News
benzinga.com
INmune Bio Submits Its CORDStrom Platform Patent Application Into The U.S. National Phase Before USP
Submission advances a key element of the Company’s global intellectual property strategy for its nex
globenewswire.com
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable Internati
Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Prog
benzinga.com
The UK Medicines & Healthcare Products Regulatory Agency Approves The Pediatric Investigation Plan F
INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on
globenewswire.com
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
Approval of pediatric strategy validates clinical data package and accelerates the regulatory path f
benzinga.com
INmune Bio Receives Official Accepted Meeting Minutes From Recent Pre-MAA Scientific Advice Meeting
MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions co
benzinga.com
INmune Bio Announces Results From Exploratory Chi-Separation MRI Imaging Analyses From MINDFuL Phase
XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46;